Result for
Tag: immunity
January 22, 2021
Effective Virus-Neutralizing Activities in Antisera from the First Wave of Severe COVID-19 Survivors
A serological study of specimens from 104 people who survived severe COVID-19 infections demonstrated that neutralizing antibodies to SARS-CoV-2 persisted for at least six months. Researchers also found that although IgG levels among severe COVID-19 patients at the convalescent phase were generally lower compared to those at the acute phase, the antibodies in serum from…
January 21, 2021
Impact of SARS-CoV-2 B.1.1.7 Spike Variant on Neutralisation
[pre-print, not peer reviewed] Sera from participants who received the first dose of the Pfizer vaccine BNT162b2 three weeks prior had no reduction in neutralizing activity against a pseudovirus with the three key spike protein mutations (N501Y, A570D, and 69/70 deletion) in the SARS-CoV-2 B.1.1.7 variant with higher transmission potential, compared to the wild-type SARS-CoV-2…
Seroprevalence of Anti‐SARS‐CoV‐2 IgG Antibodies in Children with Household Exposure to Adults with COVID‐19: Preliminary Findings
In a study of 30 families with a documented COVID-19 index case, the SARS-CoV-2 seroprevalence based on IgG antibody results was similar among adults (59%) and children (52%), despite twice as many children being previously diagnosed with COVID-19. Seroprevalence was also similar among children <5 (50%) and older than 5 years (54%). Buonsenso et al….
January 20, 2021
Neutralization of SARS-CoV-2 Lineage B.1.1.7 Pseudovirus by BNT162b2 Vaccine-Elicited Human Sera
[Pre-print, not peer-reviewed] A study comparing two SARS-CoV-2 non-replicating laboratory-produced pseudoviruses bearing either the spike proteins of the Wuhan reference strain or the B.1.1.7 variant strain concluded that it was unlikely that the new variant would escape immune effectors induced by the Pfizer/BioNTech vaccine (BNT162b2). No biologically significant difference in neutralization activity against the two…
Do Antibody Positive Healthcare Workers Have Lower SARS-CoV-2 Infection Rates than Antibody Negative Healthcare Workers Large Multi-Centre Prospective Cohort Study (the SIREN Study) England June to November 2020
Prior history of SARS-CoV-2 infection was associated with an 83% lower risk of infection in a large, multicenter, prospective cohort study (SIREN) of healthcare workers in England, with median protective effect observed five months following primary infection. The incidence between June 18-November 9, 2020 was 3.3 reinfections per 100,000 person days in the previously-infected cohort,…
January 19, 2021
Evolution of Antibody Immunity to SARS-CoV-2
Serological analysis in a cohort of 87 SARS-CoV-2 recovered individuals show that between 1.3 and 6.2 months after infection, IgM and IgG anti-spike receptor binding domain (RBD) antibody titers decrease, and neutralizing activity declines by 5-fold. In contrast, levels of RBD-specific memory B cells remain largely unchanged. Antibodies expressed by the memory B cells at…
January 11, 2021
6-Month Consequences of COVID-19 in Patients Discharged from Hospital: A Cohort Study
A cohort study following patients recovering from COVID-19 in Wuhan, China found that fatigue or muscle weakness (63%) and sleep difficulties (26%) were the most commonly reported symptoms during the 6 months post-discharge. Anxiety or depression was reported among 23% of patients. In a comparison of laboratory values during the acute phase of illness versus…
January 8, 2021
Misinformation about COVID-19: Evidence for Differential Latent Profiles and a Strong Association with Trust in Science
Agley et al. found that believing misinformation about SARS-CoV-2 may not keep people from simultaneously believing in the scientifically accepted explanation for the novel virus’s origins. Among a sample of 660 US-based users of Mechanical Turk (MTurk), 70% of people believed the scientific consensus about the virus originating in animals and rejected related conspiracy theories….
Neutralization of N501Y Mutant SARS-CoV-2 by BNT162b2 Vaccine-Elicited Sera
[pre-print, not peer-reviewed] Sera from people vaccinated with the Pfizer-BioNTech mRNA vaccine (BNT162b2) (n=20) had equivalent neutralizing antibody titers to the SARS-CoV-2 strain on which the vaccine was based and a laboratory-developed SARS-CoV-2 strain carrying a N501Y substitution, which is one of the mutations associated with rapidly spreading variants in the United Kingdom and South…
January 7, 2021
A Longitudinal Study of SARS-CoV-2-Infected Patients Reveals a High Correlation between Neutralizing Antibodies and COVID-19 Severity
Serum samples from a cohort of 140 SARS-CoV-2 positive patients suggest that increasing symptom severity is correlated with higher neutralizing antibody (nAb) titers. Only 1 of 44 patients admitted to the ICU did not develop a nAb response by the time of sampling, while nAb response was more heterogenous and less frequently observed among hospitalized…
Previous page Next page